Article

Upsher-Smith Launches Fluvoxamine Maleate Tablets

Upsher-Smith has launched fluvoxamine maleate tablets in 25 mg, 50 mg, and 100 mg strengths.

Upsher-Smith Laboratories, LLC (Upsher-Smith) has announced the launch of fluvoxamine maleate tablets in 25 mg, 50 mg and 100 mg strengths. The fluvoxamine tablet market had U.S. sales of approximately $28 million for the 12 months ending September 2019, according to IQVIA.

Reference

Upsher-Smith Launches Fluvoxamine Maleate Tablets. PR Newswire. Published January 10, 2020. https://www.prnewswire.com/news-releases/upsher-smith-launches-fluvoxamine-maleate-tablets-300984779.html. Accessed January 14, 2020.

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen | stock.adobe.com
Related Content
RSV virus, Respiratory syncytial virus, human orthopneumovirus, is a common, contagious airborne virus that causes infections of the respiratory tract 3d rendering - Image credit: catalin | stock.adobe.com
November 25th 2024

Study Results Show 1 in 20 Adults With RSV Are Hospitalized

Kennedy Ferruggia, Assistant Editor
Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes
November 21st 2024

Public Health Matters: Pharmacists as Frontline Health Providers: Collaborating for Better Patient Outcomes

Christina M. Madison, PharmD, FCCP, AAHIVP
Child with asthma -- Image credit: uwimages | stock.adobe.com
November 25th 2024

Community Health Care Workers Connect Children With Asthma to Care in Trigger Environments

Gillian McGovern, Assistant Editor
Public Health Matters podcast logo
September 19th 2024

Public Health Matters: The Difference Between Misinformation and Disinformation, and How Information Can Inform Evidence-Based Decisions

Streptococcus pneumonia bacteria cells.
November 22nd 2024

Decision to Receive Pneumococcal Vaccine Among Older Adults Is Multi-Factorial, Influenced by Multidimensional Interventions

Luke Halpern, Assistant Editor
FCS, Plozasiran, Cholesterol, Familial Chylomicronemia Syndrome| Image Credit: © ugreen | stock.adobe.com
November 22nd 2024

Arrowhead Pharmaceuticals Submits FDA Application for Plozasiran in Familial Chylomicronemia Syndrome

Ashley Gallagher, Associate Editor